Leading with ingenuity and resolve

Cenerimod, a highly selective S1P1 receptor modulator, is an investigational drug that potentially offers a novel approach for the treatment of SLE, commonly known as lupus, a disease with a significant impact on patients and limited treatment options.

Cenerimod, a highly selective S1P1 receptor modulator, is an investigational drug that potentially offers a novel approach for the treatment of lupus nephritis, a serious manifestation of systemic lupus erythematosus (SLE) that is caused by inflammation of the kidneys. It affects up to half of people living with SLE and can lead to serious complications including chronic kidney disease and end-stage renal disease that significantly impair kidney function and overall health.

Effexor^® (venlafaxine hydrochloride) is a serotonin-noradrenaline reuptake inhibitor (SNRI) under evaluation in Japan to treat adults with GAD, an indication for which no other treatment option is currently approved in the country.

The company’s investigational fast-absorbing oral meloxicam is being evaluated for the treatment of moderate-to-severe acute pain, inclusive of post-operative pain. Acute pain, which commonly results from surgical procedures, trauma, or acute illness, affects over 80 million patients annually in the U.S. Despite the scale of this need, treatment options that combine rapid onset, meaningful pain control, and opioid reduction potential remain limited—highlighting the opportunity for differentiated non-opioid therapies in the acute pain setting.

Influvac^® High Dose is a strategic lifecycle extension of our current Influvac^® vaccine in Europe. Influvac^® High Dose has the potential to offer patients – particularly those aged 60 and older – an enhanced immune response compared with the standard dose.

Nefecon^® (budesonide) is being investigated in Japan as a specialty drug, for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN). IgAN, also known as Berger's disease, is a rare and serious progressive autoimmune disease in which up to 50 percent of patients end up at risk of developing end stage renal disease thus requiring dialysis or a kidney transplant.

Norelgestromin and Low Ethinyl Estradiol Weekly Patch aims to address an important need for women seeking a reversible birth control method that offers a lower dosage of estrogen in a weekly patch with potential best-in-class adhesion performance.

Norelgestromin Weekly Patch (MR-130A-01) is a progestin only contraceptive transdermal system designed for women with medical comorbidities—including those with a BMI above 30 kg/m2 and for those who prefer to avoid estrogen-related exposure with known safety risks.

Phentolamine ophthalmic solution 0.75% is being evaluated for the treatment of presbyopia, which is the progressive loss of the ability to focus on close objects that results in blurred near vision and eye strain, particularly in dim lighting conditions. Presbyopia typically becomes noticeable in the early to mid-40s and is a nearly universal condition that, when uncorrected, contributes significantly to vision-related disability. Presbyopia leads to symptoms like eye strain and blurred near vision, impacting daily tasks and productivity and affects nearly 128 million people in the U.S.—about 90% of adults over 45.

Phentolamine ophthalmic solution 0.75% is being evaluated for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. The U.S. Food and Drug Administration granted Fast Track designation to MR-142 for the treatment of significant, chronic night driving impairment with concomitant increased risk of motor vehicle accidents and debilitating loss of best spectacle corrected mesopic vision in keratorefractive patients with photic phenomena (e.g., glare, halos, starburst).

Pitolisant is an antagonist/inverse agonist that selectively binds to the histamine H3 receptor, an autoreceptor located in the presynaptic region of the histamine-containing neurons in the brain that plays a critical role in regulating sleep and wake rhythm. Pitolisant is being evaluated in Japan for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy and for the treatment of excessive daytime sleepiness associated with obstructive sleep apnea syndrome.

Selatogrel is a potent, fast-acting, reversible, and highly selective P2Y12 inhibitor, being evaluated for the treatment of AMI in patients with a history of AMI. The U.S. Food and Drug Administration granted Fast-Track designation to selatogrel for the treatment of suspected AMI. Globally, AMI is one of the leading causes of death and more than 10 million people have a heart attack each year.

Sotagliflozin is an oral inhibitor of the sodium-glucose cotransporter SGLT2 and SGLT1, two proteins involved in glucose regulation. SGLT2 mediates glucose and sodium reabsorption in the kidney, whereas SGLT1 facilitates glucose and sodium absorption in the gastrointestinal tract. Beyond the intestine, SGLT1 is also expressed in the heart and vascular endothelium, where it may modulate cellular stress and inflammatory pathways, suggesting potential effects that extend beyond glycemic control. Sotagliflozin has been evaluated across multiple patient populations, including those with heart failure, diabetes, and chronic kidney disease, in clinical studies involving approximately 20,000 patients.

In Japan, Aculys Pharma received marketing approval for Spydia Nasal Spray for the treatment of status epilepticus in patients 2 years or older in June 2025. This is the first intranasal anti-seizure medication approved in Japan for the treatment of status epilepticus or seizures with potential progression to status epilepticus. It is also the first rescue medication approved for adults for out-of-hospital use.

(1) Acquired exclusive rights in Japan and certain markets in the Asia-Pacific region, including Australia, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, New Zealand, Philippines, South Korea, Thailand and Vietnam.